This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Impact Of Patent Expiration On Key Drugs Categories For 2012-2016 - A Survey Report

NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report

http://www.reportlinker.com/p01055031/Impact-of-Patent-Expiration-on-Key-Drugs-Categories-for-2012-2016----A-Survey-Report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

TechNavio's analysts have conducted a survey on Impact of Patent Expiration on Key Drugs Categories for 2012-2016. The survey assessed the Impact of Patent Expiration on several key drugs categories such as Antipsychotic drugs, Antibiotics, ADHD drugs, Antacid drugs, Antiplatelet drugs, Asthma drugs, Diabetes drugs, Arthritis drugs, HIV drugs, Epilepsy drugs, and Cardiovascular drugs. The survey also covers the strategies adopted before patent expiration, strategies adopted to counter patent expirations, organizational impacts, and their sales impacts. Based on the overall factors, the impact of patent expiration on key drugs categories was studied for the period 2012-2016.

TechNavio's report, Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report, has been prepared based on responses from over 200 participants across patented drug manufacturers, generic drug manufacturers, and a combination of both. The survey participants were selected from more than 15 top countries in the Global Pharmaceuticals market.

The vendors mentioned in the report are ABX GmbH, Ache Laboratorios SA, ACI Limited, Ajanta Pharma Ltd., Alphapharm Pty Ltd., AstraZeneca Europe, AstraZeneca India, Astrazeneca do Brasil LTDA, Baxter Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, CCL Pharmaceuticals Pvt. Ltd., Cipla Ltd., Covidien India Healthcare Limited, Dr Reddy's Laboratories Ltd., Eurofarma Laboratories Ltd., Ferring Pharmaceuticals, Genus Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Healthcare Pharmaceuticals Ltd., Hospira Australia Pty Ltd., iNova Pharmaceuticals, LEO Pharma, Medley Pharmaceuticals Ltd., Merck Sharp & Dohme, MSD Pharmaceuticals Pvt. Ltd., Novartis International AG, Novartis de Colombia, Novartis farma Italy, Panacea Biotec Ltd., Pfizer Inc., PharmOut Pty Ltd., APP Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sandoz GmbH, Sandoz India Pvt Ltd., Sanofi SA, Schwabe Pharmaceuticals, Torrent Pharma, Vifor Pharma Ltd., Wanbury Ltd, and Wockhardt Ltd.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,777.92 -0.23 -0.00%
S&P 500 2,063.95 +2.72 0.13%
NASDAQ 4,755.6560 +7.26 0.15%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs